| Structural basis of Keap1 interactions with Nrf2 P Canning, FJ Sorrell, AN Bullock Free Radical Biology and Medicine 88, 101-107, 2015 | 529 | 2015 |
| Structural basis for Cul3 protein assembly with the BTB-Kelch family of E3 ubiquitin ligases P Canning, CDO Cooper, T Krojer, JW Murray, ACW Pike, A Chaikuad, ... Journal of Biological Chemistry 288 (11), 7803-7814, 2013 | 299 | 2013 |
| Keap1, the cysteine-based mammalian intracellular sensor for electrophiles and oxidants AT Dinkova-Kostova, RV Kostov, P Canning Archives of biochemistry and biophysics 617, 84-93, 2017 | 288 | 2017 |
| Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor HG Kim, L Tan, EL Weisberg, F Liu, P Canning, HG Choi, SA Ezell, H Wu, ... ACS chemical biology 8 (10), 2145-2150, 2013 | 154 | 2013 |
| Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds A Cruz-Migoni, P Canning, CE Quevedo, CJR Bataille, N Bery, A Miller, ... Proceedings of the National Academy of Sciences 116 (7), 2545-2550, 2019 | 119 | 2019 |
| Inflammatory signaling by NOD-RIPK2 is inhibited by clinically relevant type II kinase inhibitors P Canning, Q Ruan, T Schwerd, M Hrdinka, JL Maki, D Saleh, ... Chemistry & biology 22 (9), 1174-1184, 2015 | 110 | 2015 |
| Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors P Canning, L Tan, K Chu, SW Lee, NS Gray, AN Bullock Journal of molecular biology 426 (13), 2457-2470, 2014 | 108 | 2014 |
| Structure–activity relationship of 3, 5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants AH Mohedas, Y Wang, CE Sanvitale, P Canning, S Choi, X Xing, ... Journal of medicinal chemistry 57 (19), 7900-7915, 2014 | 93 | 2014 |
| CDKL family kinases have evolved distinct structural features and ciliary function P Canning, K Park, J Goncalves, C Li, CJ Howard, TD Sharpe, LJ Holt, ... Cell reports 22 (4), 885-894, 2018 | 59 | 2018 |
| Molecular dynamics, crystallography and mutagenesis studies on the substrate gating mechanism of prolyl oligopeptidase K Kaszuba, T Róg, R Danne, P Canning, V Fülöp, T Juhász, Z Szeltner, ... Biochimie 94 (6), 1398-1411, 2012 | 59 | 2012 |
| Crystal structures of Trypanosoma brucei oligopeptidase B broaden the paradigm of catalytic regulation in prolyl oligopeptidase family enzymes P Canning, D Rea, RE Morty, V Fülöp PloS one 8 (11), e79349, 2013 | 43 | 2013 |
| New strategies to inhibit KEAP1 and the Cul3-based E3 ubiquitin ligases P Canning, AN Bullock Biochemical Society Transactions 42 (1), 103-107, 2014 | 35 | 2014 |
| Structural basis for ASPP2 recognition by the tumor suppressor p73 P Canning, F von Delft, AN Bullock Journal of molecular biology 423 (4), 515-527, 2012 | 22 | 2012 |
| Lessons from LIMK1 enzymology and their impact on inhibitor design E Salah, D Chatterjee, A Beltrami, A Tumber, F Preuss, P Canning, ... Biochemical Journal 476 (21), 3197-3209, 2019 | 16 | 2019 |
| Fragment-based target screening as an empirical approach to prioritising targets: a case study on antibacterials P Canning, K Birchall, CA Kettleborough, A Merritt, PJ Coombs Drug Discovery Today 25 (11), 2030-2037, 2020 | 13 | 2020 |
| Correction to Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor HG Kim, L Tan, EL Weisberg, F Liu, P Canning, HG Choi, S Ezell, Z Zhao, ... Acs Chemical Biology 9 (3), 840-840, 2014 | 5 | 2014 |
| Competitive SPR using an intracellular anti-LMO2 antibody identifies novel LMO2-interacting compounds P Canning, C Bataille, N Bery, S Milhas, A Hayes, F Raynaud, A Miller, ... Journal of Immunological Methods 494, 113051, 2021 | 3 | 2021 |
| Evaluating the druggability of TrmD, a potential antibacterial target, through design and microbiological profiling of a series of potent TrmD inhibitors AJ Wilkinson, N Ooi, J Finlayson, VE Lee, D Lyth, KS Maskew, R Newman, ... Bioorganic & Medicinal Chemistry Letters 90, 129331, 2023 | 1 | 2023 |
| Human LIM domain kinase 1 (LIMK1), kinase domain S Mathea, E Salah, A Beltrami, A Chaikuad, T Hanke, R Kashima, ... A Target Enabling Package 10, 2017 | 1 | 2017 |
| The prolyl oligopeptidase family enzymes: structural basis of inhibition P Canning University of Warwick, 2009 | | 2009 |
